RT Journal Article
SR Electronic
T1 Inactivated Poliovirus Vaccine Induces Antibodies that Inhibit RNA Synthesis of SARS-CoV-2: An open-label, pre-post vaccine clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.05.21264598
DO 10.1101/2021.10.05.21264598
A1 Comunale, Brittany A.
A1 Jackson-Ward, Erin
A1 Jiang, Yong
A1 Ward, Laura P.
A1 Liu, Qianna
A1 Ji, Lyuqing
A1 Lai, Michelle
A1 Engineer, Lilly
A1 Comunale, Roderick A.
A1 Xie, Qiyi
YR 2021
UL http://medrxiv.org/content/early/2021/10/07/2021.10.05.21264598.abstract
AB Background Poliovirus vaccination induces an adaptive humoral immune response; in vitro experiments show polio-immune sera contain antibodies against the poliovirus RNA transcriptase that cross-react with SARS-CoV-2. While structural similarities between poliovirus and SARS-CoV-2 could have major implications for the COVID-19 response worldwide, polio-induced immune responses against SARS-CoV-2 have not been confirmed in prospective clinical trials.Objective To evaluate whether immune sera from adults who recently received inactivated poliovirus vaccination (IPV) can block SARS-CoV-2’s ability to synthesize RNA.Intervention IPV intramuscular injection.Measurements Pre-inoculation and 4-weeks post-inoculation sera were tested for anti-3Dpol (RNA-dependent RNA polymerase, RdRp) antibodies using enzyme-linked immunosorbent assays (ELISA). To assess IPV’s ability to induce antibodies that inhibit SARS-CoV-2 RNA synthesis, immune-based detection assays tested RdRp enzymatic activity in polio-immune sera.Results 298 of the 300 enrolled participants completed both on-site visits. Comparing pre-inoculation to 4-week samples, 85.2% of participants demonstrated an increase in anti-3Dpolantibodies against RdRp proteins. Among tested post-inoculation samples, 94.4% demonstrated inhibition of SARS-CoV-2 RNA synthesis. Few inoculation-related side effects were reported (2.0%), all were minor.Limitations Participants were not systematically tested for COVID-19, though known exposures were reported and positive results (1.7%) were documented.Conclusion IPV can induce antibodies that inhibit SARS-CoV-2 RNA synthesis, minimizing the risk of viral replication in infected individuals. This finding has practical implications for resource-deficient areas that may have limited access to newly developed COVID-19 vaccines and/or areas with low COVID-19 vaccination rates due to hesitancy.Funding Source Private donors.Registration ClinicalTrials.gov: NCT04639375.Competing Interest StatementYJ reports contract service fees from GeneScan Diagnostics. RC reports contract service fees from RAC, Inc. QX holds an executive position in E-Mo Biology, Inc. E-Mo Biology, Inc. has a patent pending. The remaining authors declare that they have no conflicts of interest.Clinical TrialNCT04639375Funding StatementThis study was fully funded by a private source in Southern California. Funders provided finances only and had no involvement in the research activities (project initiation, study design, data collection, analysis, interpretation, results, and inference). All authors had full access to the full data in the study and accept responsibility to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was obtained from Advarra IRB (Columbia, MD).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe original contributions generated for this study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.